Focal therapy for prostate cancer
Treating only the tumour area within the prostate.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 5, 8, 7, 12, 12.
New guidelines and consensus this year
- NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026J Natl Compr Canc Netw2026 May
- The Italian Society of Urology Statement on focal therapy for localized prostate cancerMinerva Urol Nephrol2026 Feb
All papers from the last 12 months
149 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Salvage therapy for radiorecurrent prostate cancer: beyond equipoise - a call for biomarker-driven stratificationTransl Oncol2026 NovPMID 42731418
- Patient selection for prostate cancer focal therapy guided by mpMRI-PSMA PET concordance and pathology reviewBJU Int2026 NovPMID 42581662
- Updating of the AUA/ASTRO Prostate Cancer Guidelines: A Constant Work in ProgressJ Urol2026 NovPMID 42467657
- Transurethral ultrasound ablation (TULSA) for prostate cancer: a systematic review and meta-analysisBJU Int2026 Oct 12PMID 42864969Review
- Cribriform and intraductal carcinoma in prostate cancer - implications for risk stratification and therapeutic decision-makingNat Rev Urol2026 Oct 9PMID 42855542Review
- Partial vs. whole-gland salvage hifu after radiotherapy failure: oncological and functional outcomesWorld J Urol2026 Oct 5PMID 42831949
- FOCS-24: An integrated oncologic-functional endpoint and its preoperative nomogram after focal therapy for localized prostate cancerUrol Oncol2026 OctPMID 42760039
- Editorial comment: FOCS-24: An integrated oncologic-functional endpoint and its preoperative nomogram after focal therapy for localized prostate cancerUrol Oncol2026 OctPMID 42760037
- Trans-perineal prostate biopsy-Prognostic factors for "no prostate tissue" in biopsy coresUrol Oncol2026 OctPMID 42557190
- Cancer-specific mortality in high-risk or very high-risk prostate cancer patients treated with focal therapy vs. radical prostatectomyUrol Oncol2026 OctPMID 42557188
More urology trends
All specialties →PSMA PET in prostate cancer
PSMA PET imaging for staging and recurrence of prostate cancer.
Key point: PSMA-PET/CT is recommended only when PSA exceeds 0.2 μg/L, reporting should follow PSMA-RADS, and it is preferred over lymph-node dissection for staging.
Male infertility
Male infertility and trends in semen quality.
Key point: Male infertility management should be couple-centered, integrating the female partner's reproductive timeline to avoid preventable delays in effective therapy.
Robotic partial nephrectomy
Robot-assisted partial nephrectomy for kidney tumours.
Beta-3 agonists for overactive bladder
Mirabegron and vibegron for overactive bladder.
Key point: Vibegron appears to rank more favourably for urgency, urgency incontinence and maximum voided volume, while mirabegron ranks more favourably for 24-hour frequency.
BCG-unresponsive bladder cancer
New options for non-muscle invasive bladder cancer after BCG fails.
Preventing recurrent UTIs
Vaccines and non-antibiotic prevention of recurrent urinary tract infections.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"focal therapy"[tiab] AND prostate[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.